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Thyroid hormones (THs) are key regulators of metabolism. The thyroid gland produces 
both thyroxine (T4) and triiodothyronine (T3). T4 is the main product and is converted in 
the periphery via deiodination to T3 which is the main biologically active TH. The 
production of THs is regulated by thyrotrophin (TSH) in response to TSH releasing 
hormone (TRH). This, in turn, is regulated by a negative feedback mechanism related to 
serum levels of free T3 and T4 (fT3 and fT4). Binding of T3 to TH receptors (TR) followed by 
binding of T3-TR complex to thyroid response elements within TH responsive genes leads 
to changes in gene transcription. These effects of TH are present through a wide number of 
tissues and organ systems including the cardiovascular system. 
2. Thyroid hormone and its actions on the cardiovascular system 
The effects of TH on both the heart and peripheral vascular system have been well 
documented1-9. In states of TH excess (hyperthyroidism) a high cardiac output state 
secondary to increased heart rate and contractility with a reduction in systemic vascular 
resistance (SVR) is seen. In hypothyroidism, the reciprocal effects are observed. The 
reduction that is seen in SVR is an early response to TH administration10, 11. This may be 
partly due to the release of local vasodilators liberated as a result of increasing metabolic 
activity and oxygen consumption. The effects of TH on vascular tone may also be 
attributable to its direct effects on arteriolar smooth muscle. Intracoronary administration of 
TH in Langendorff preparations has been demonstrated to lead to coronary vasodilatation 
within 15 seconds12 and in normal human subjects reductions in SVR are seen within 
minutes of administration11, with this effect lasting for several hours when administered 
intra-operatively13. 
TH is able to manifest its effects on the cardiovascular system at both a genomic and non-
genomic level; this means that with administration of TH there are immediate non-
genomic cardiovascular consequences6, 11, 14, followed by later genomic alterations which 
include alterations in the expression of the beta one adrenergic receptor (ADRB1). 
However, despite increasing receptor expression, there is a paucity of evidence that T3 
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administration increases sensitivity to catecholamines15, 16. TH also acts upon the 
expression of calcium handling proteins within the myocyte including the sarcoplasmic 
reticulum calcium ATPase (SERCA) and its negative regulator phospholamban (PLB). 
Administration of T3 increases the level of SERCA mRNA and protein and also lowers 
phospholamban levels and increases its phosphorylation state, which enhances the 
activity of SERCA17-22. The combined effect of these changes is an increase in the force of 
contraction and speed of diastolic relaxation. 
3. The consequences of the hypo-and hyperthyroid states 
Hypothyroid patients may have symptoms or signs associated with heart failure including 
dyspnoea, oedema, cardiomegaly and effusions. Low cardiac output in these patients is due 
to decreased heart rate, reduced ventricular filling and decreased myocardial contractility. 
Hypothyroidism is a risk factor for coronary artery disease23, the incidence of angina and 
myocardial infarction is however lower and this may relate to a reduction in metabolic 
requirements of the myocardium. Hypothyroidism is associated with hypertension, 
secondary to alterations in peripheral vascular resistance. Prolongation of the cardiac action 
potential and QT interval are also noted 24 and this leads to an increased risk of ventricular 
arrhythmias in this group. Supplementation with TH can lead to a reversal of some of these 
cardiovascular manifestations25. However, in the setting of cardiac surgery post-operative 
reductions in circulating THs have been demonstrated to be associated with an increase in 
the occurrence of atrial fibrillation26, 27. The vast majority of patients who are hypothyroid 
are receiving hormone replacement therapy and are therefore euthyroid at the time of 
surgery. However, in theory, in the untreated hypothyroid patient acute TH replacement 
could worsen myocardial ischaemia if myocardial oxygen consumption were increased in 
the face of fixed oxygen delivery28. Surgery in the hypothyroid patient may be performed 
without increased risk. In patients with untreated mild to moderate hypothyroidism 
undergoing cardiac surgery, Drucker reported no adverse effects29 and Syed et al. reported 
no increase in complications in patients with known hypothyroidism on treatment who 
were biochemically hypothyroid over those that were biochemically euthyroid without 
utilising additional TH replacement therapy30. O’Connor et al31 in undiagnosed patients 
with hypothyroidism have reported the occurrence of severe myxoedema post cardiac 
surgery leading to significant haemodynamic compromise which recovered with 
replacement TH therapy. 
Hyperthyroid patients commonly have a resting tachycardia. The most common rhythm 
disturbances are supraventricular arrhythmias including atrial fibrillation which predispose 
to thromboembolic diseases. Cardiac output may be supranormal (between 50-300% higher 
than in normal subjects). This is secondary to increases in heart rate, left ventricular 
contractility, blood volume and a reduction in SVR8. Improvements in LV systolic and 
diastolic function are believed to be modulated by changes in the expression of contractile 
and calcium regulating proteins (SERCA and PLB). Even though cardiac output is high it 
may be suboptimal at times of exertion32, due to an inability to further augment heart rate or 
lower systemic vascular resistance. Long-term follow-up of patients with hyperthyroidism 
reveals an increased cardiovascular and cerebrovascular mortality. This may partially be 
related to the increased rate of supraventricular dysrhythmias33,34. In the setting of overt 
clinical and biochemical hyperthyroidism surgery should be deferred if possible, until the 
patient can be rendered euthyroid in order to avoid thyroid storm. 
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4. The non-thyroidal illness syndrome 
In response to severe physiological stress including cardiac surgery, changes in circulating 
concentrations of T3, T4 and TSH occur. The term non-thyroidal illness syndrome (NTIS) 
has been used to describe this phenomenon as it makes no presumption regarding the 
metabolic state of the patient. Whether hormone supplementation to correct these 
abnormalities is beneficial or not is unproven and much debated35. There are a variety of 
mechanisms that could potentially explain the biochemical profile observed in the NTIS 
including modifications of the hypothalamic-pituitary-thyroid axis, altered binding of TH to 
circulating proteins, modified entry of TH into tissues, changes in TH metabolism due to 
modification of the iodothyronines deiodinases as well as changes in TH receptor expression 
or function36. Circulating levels of T3 decrease within two hours of severe physiological 
stress and this is thought to reflect a reduction in the peripheral conversion of T4 to T337, 38. 
The most common abnormality observed in severely ill hospitalised patients is a low T3 
syndrome, which occurs in up to 70% of patients39. Reduction in concentrations of free T3 
(fT3) in hospitalised patients have been demonstrated to be predictive of mortality40. 
Deficiencies in TH metabolism have also been demonstrated to occur at a tissue level with a 
positive correlation between circulating and tissue TH levels41. As T3 levels fall reverse T3 
(rT3, an inactive metabolite) increases. With increasing severity of illness, T4 levels also 
begin to fall (low T3-low T4 syndrome). Whether these observed responses are energy 
conserving to reduce metabolic rate or pathological requiring TH supplementation still 
remains a matter of debate. 
5. The effects of cardiopulmonary bypass on circulating levels of thyroid hormone 
With the stress response associated with surgery, concentrations of fT3 are noted with a more 
precipitous decline following institution of cardiopulmonary bypass (CPB). These further 
reductions may relate either to a secondary increase in the stress response or to 
haemodilution42. Occurrence of the NTIS has been well documented in the context of both 
adult and paediatric cardiac surgery13, 43, 44. Supplementation with both oral and intravenous 
T3 has been demonstrated to raise circulating T3 levels to normal or supra-normal levels13, 45. 
It was believed that occurrence of NTIS may be related to the stress response and 
haemodilution associated with CPB. However, data from patients undergoing cardiac 
surgery without CPB have demonstrated that the reductions in T3 that have previously been 
observed in trials of patients undergoing cardiac surgery utilising CPB also occur in the off-
pump group to a similar magnitude. This implies that the NTIS during cardiac surgery is a 
non-specific stress response and CPB is not the only contributing factor to its occurrence46, 47. 
6. The rationale for treatment of the NTIS in patients undergoing cardiac surgery 
If the NTIS is truly a maladaptive phenomenon, therapy with TH supplementation may 
have potentially beneficial effects by rectifying the observed abnormalities and increasing 
myocardial performance via both genomic and non-genomic mechanisms, thereby having 
the potential to improve patient outcomes. 
In addition to the beneficial haemodynamic effects seen with T3 administration, there is a 
mounting body of both animal and clinical data suggesting that T3 may have a positive 
influence on protecting the myocyte following ischaemia. Two weeks administration of T4, 
followed by ischaemia and reperfusion in an isolated rodent heart model has been 
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demonstrated to improve post-ischaemic function in T4 treated hearts with attenuation of 
activation of the p38 mitogen activated protein kinase (MAPK)48. In a murine coronary 
artery ligation model of acute myocardial ischaemia, animals administered T3 demonstrated 
improved haemodynamic function as well as reducing ischaemia induced apoptosis with an 
associated increase in Akt signalling compared with placebo49. In addition, following a 
period of global ischaemia in a rodent isolated heart model, T3 administered at reperfusion 
led to a reduction in apoptotic damage with reduced caspase-3 activity and activated p38 
MAPK after one hour of reperfusion. These effects were associated with improved recovery 
of post-ischaemic function when compared to control hearts50. In patients undergoing 
isolated coronary artery bypass graft surgery (CABG) administration of T3 at reperfusion 
and for six hours after has been demonstrated to improve haemodynamic function in the 
immediate post-operative period with an associated reduction in the release of troponin I 
compared with placebo therapy51. 
7. Development of the use of thyroid hormone as an inotropic agent during cardiac 
surgery 
The salutary effects of acute T3 supplementation have previously been demonstrated in a 
number of animal models that aimed to recreate the post-ischaemic dysfunction observed 
after cardiac surgery. 
Novitzky demonstrated in both a porcine and canine models of ischaemia-reperfusion that 
T3 administration was able to attenuate the post-ischaemic left ventricular dysfunction 
compared with control52, 53. In isolated canine hearts subjected to hyperkalaemic arrest, 
Klemperer demonstrated that T3 supplementation following reperfusion led to an increase 
in preload recruitable stroke work area. This occurred without an increase in myocardial 
oxygen consumption, suggesting that administration of T3 in patients with a myocardial 
oxygen debt does not exacerbate this debt54. 
8. Thyroid hormone supplementation in paediatric cardiac surgery 
There are a number of randomised controlled trials of T3 supplementation in paediatric 
cardiac surgery. These studies have been mainly performed in heterogeneous groups of 
patients with a variety of CPB and temperature management strategies, age ranges and 
diagnoses. 
During paediatric cardiac surgery, Murzi et al. noted a significant reduction in fT3 with a 
nadir at 48 hours post-operatively and levels still below baseline values up to six days post-
operatively. Levels of fT4 were reduced at six hours with a nadir at 72 hours, however, the 
magnitude of the decline was not as great as that seen with fT343. Saatvedt et al. 
demonstrated in a population of paediatric cardiac surgical patients a reduction in fT3 and 
TSH with an increase in fT4 in the first 48 hours following surgery55. They attributed the 
increase in fT4 to the competition with free fatty acids (which are liberated by systemic 
heparinisation) in binding to plasma proteins, thus increasing fT4 levels. Marks et al 
demonstrated a reduction in TSH to lower limits of normal and reduced fT4 total T3 and fT3 
index to below normal ranges and correlations between increased intensive care unit stay 
and mechanical ventilation to the degree of NTIS was observed44. 
Bettendorf et al conducted a randomised double-blind placebo controlled trial of 40 
paediatric patients randomised to receive either T3 (2g.kg-1 on the first post-operative day, 
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followed by 1g.kg-1 on subsequent days) or placebo for up to 12 days following surgery. T3 
therapy led to significantly higher serum circulating TH levels and the mean change in 
cardiac index was significantly higher in those that received T3 (20.4% vs. 10.0%, p=0.004). A 
sub group of patients with increased operative and CPB times were demonstrated to have 
improvements in systolic function measured by transthoracic echocardiography for T3 
treated patients. The level of post-operative inotropic support was not different between 
groups56. 
In 28 children under seven years of age, Chowdhury et al randomised patients to receive 
either T3 at an infusion rate of 0.05-0.15g.kg-1.h-1 to maintain serum T3 levels within a 
normal range or placebo for a maximum of seven days57.Sub-group analysis of the nine 
neonatal patients (less than one month) demonstrated a reduction in inotrope and 
therapeutic intervention scores. No significant difference was noted in the main trial group. 
Mackie et al reported on the effects of T3 supplementation (0.05g.kg-1.h-1) following 
termination of CPB and continued for a maximum of 48 hours in a randomised double-blind 
placebo controlled trial (n= 42) on neonates undergoing Norwood repair or repair of 
interrupted aortic arch with ventricular septal defect. Administration of T3 was noted to be 
safe but did not improve haemodynamic function. T3 treated patients had a shorter time to 
negative fluid balance compared with controls58. 
The largest randomised controlled trial to date of T3 supplementation in the paediatric 
surgical population is the triiodothyronine supplementation in infants and children 
undergoing cardiopulmonary bypass (TRICC) trial 59. Portman and colleagues randomised 
198 (analysed 193) children less than two years of age. They stratified to account for the 
heterogeneity of pathologies seen. T3 was administered as boluses of 0.4g.kg-1 prior to CPB, 
a further 0.4g.kg-1 at reperfusion, followed by three equally timed doses of 0.2g.kg-1 up to 
nine hours post reperfusion. The safety of T3 administration in this group of patients with 
complex congenital cardiac defects was noted. In the entire study group, no difference in 
haemodynamic, inotropic or post-operative outcomes were detected. However, on planned 
sub-group analysis a reduction in time to extubation, improvements in cardiac function and 
reduced inotrope requirements were noted for children less than five months of age. 
9. Thyroid hormone supplementation in adult cardiac surgery 
Novitzky performed two small randomised blinded trials assessing the administration of T3 
in patients undergoing CABG. In the first of these, 24 patients with a left ventricular ejection 
fraction (LVEF) < 30% were administered either placebo or T3 (n= 12) at aortic cross clamp 
(AXC) removal and at pre-defined intervals post-operatively. Patients treated with T3, 
demonstrated a reduction in, inotrope and diuretic requirements. In the following study (n= 
24) of this series T3 was administered to those patients with an LVEF > 40%. Those patients 
treated with T3 (n=13) demonstrated a significant increase in cardiac output with an 
associated reduction in systemic vascular resistance in the first 24 hours following removal 
of the AXC60. Following the encouraging results of these trials and the preceding animal 
work, a number of larger trials have been performed. 
Klemperer et al randomised 142 patients undergoing first time CABG with LVEF < 40% to 
receive either placebo or T3 therapy13. T3 was administered as a bolus of 0.8g.kg-1 at AXC 
removal followed by an infusion of 0.113g.kg-1.h-1 for six hours post AXC removal. 
Treatment with T3 led to supra-physiological levels of T3 (and remained significantly higher 
during T3 treatment compared to placebo) and were associated with haemodynamic 
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improvements manifest by an increase in cardiac index and reduction in SVR. No 
statistically significant difference was noted in the requirement of inotropic or 
vasoconstrictor support during the six hours of T3 therapy following surgery. The incidence 
of post-operative atrial fibrillation was significantly reduced in the T3 group61. 
Bennett-Guerro et al randomised 211 patients undergoing CABG surgery62 believed to be at 
higher risk of requiring post-operative inotropic support (LVEF < 40%, age > 65 years or 
cardiac re-operation) to receive either T3, dopamine (as a positive control) or placebo. T3 
treatment dose was again a 0.8g kg-1 bolus at AXC removal followed by an infusion of 
0.12g kg-1.h-1 for six hours, weaned over the next five hours. The dopamine group received 
5g.kg-1.min-1 for six hours, weaned over the next six hours. The post-operative low T3 state 
was prevented with T3 administration, however, this study failed to demonstrate any 
significant difference in post-operative haemodynamic performance or inotrope 
requirements for patients receiving T3 therapy. 
In a third study of patients undergoing CABG, Mullis-Jansson et al randomised 170 patients 
to receive either T3 1g kg-1 at AXC removal followed by an infusion of 1g.kg-1 for six 
hours. In this trial, T3 therapy was demonstrated to have a significant haemodynamic 
benefit with an increase in cardiac index in the 12 hours following removal of the AXC but 
with no significant reduction in the SVR. The requirement for post-operative inotropic and 
post-operative mechanical circulatory support was also reduced in patients receiving T3 
therapy. Post-operative myocardial injury as measured by biochemical markers and 
electrocardiographic criteria (assessed by an independent blinded cardiologist) was also 
reduced for patients receiving T3 therapy63. 
In a randomised trial of metabolic and hormonal therapy in patients undergoing first-time 
isolated CABG patients receiving T3 were demonstrated to have improved haemodynamic 
performance, reduced inotrope requirements and release of troponin I was significantly 
reduced for those patients administered T3 51. T3 therapy was administered as per the 
protocol originally set out in the trial by Klemperer et al13. 
In addition to the studies investigating peri-operative intravenous supplementation, the 
potential benefits of pre-operative oral administration of T3 have been investigated. Sirlak et 
al64 attempted to optimise TH levels in patients undergoing CABG with reduced LVEF 
(<30%). In this study, patients (n= 80) were randomised to receive either oral T3 therapy 
125µg per day for seven days prior to surgery and from the first post-operative day until 
time of discharge or placebo therapy. At anaesthetic induction patients in the T3 treatment 
group were demonstrated to have significantly higher levels of serum fT3 and significantly 
reduced serum levels of TSH and T4. Although both groups had reductions in serum fT3 
associated with surgery and institution of CPB, the magnitude of the effect was reduced in 
patients receiving oral T3 and with post-operative re-institution of T3 a more rapid return to 
baseline levels was noted. Although no benefit was seen in terms of improvement in 
haemodynamic performance at baseline between the groups, T3 treated patients had a 
significant increase in both cardiac index and mixed venous oxygen saturations in the first 
24 hours when compared with the placebo group. In addition, inotrope requirements, 
requirement for mechanical circulatory support and intensive care unit length of stay were 
reduced for the T3 group64. 
Kaptein and colleagues performed a meta-analysis to investigate the effects of TH therapy 
on post-operative NTIS in adults, They analysed 14 randomised controlled trials (13 of 
which were in patients undergoing cardiac surgery)45. Patients were divided into low and 
high dose intravenous T3 groups and oral T3 groups. Patients in the high dose group tended 
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towards supra-physiological concentrations of T3, whereas those in the low dose group 
were more physiological. For those patients undergoing CABG, both the low (0.0275-
0.0333g.kg-1.h-1 for 14 to 24 hours) and high (0.175-0.333g.kg-1.h-1 for six to nine hours) 
dose treatment groups demonstrated significantly increased cardiac index at four to six 
hours in pooled analyses. In the low and high dose treatment groups, serum T3 levels were 
90-108% and 241-571% of baseline values respectively. No correlation was noted between 
cardiac index (percentage of basal) and total T3 dose, implying that there may be no 
additional benefit on cardiac index with increasing T3 dose. No difference in mortality was 
noted and there was insufficient data to comment on hospital and intensive care unit stay. 
The overall conclusions of the meta-analysis were that although cardiac index was 
increased, further information is required to investigate potential deleterious effects such as 
an increase in myocardial oxygen consumption45, although this has not been demonstrated 
in animal studies54. 
10. Summary 
The NTIS is a common occurrence following cardiac surgery in both paediatric and adult 
populations. Supplementation with T3 leads to supra-normal T3 levels and has been shown 
in a number of studies to 
1. Improve haemodynamic performance 
2. Reduce inotrope requirements 
3. Reduce the need for mechanical circulatory support 
4. Attenuate myocardial injury. 
As yet none of these trials has demonstrated a major benefit in terms of a significant 
reduction in post-operative morbidities and mortality and further work is required to 
ascertain the optimal dose and timing of administration to maximise the potential benefits of 
T3 therapy in the post-operative cardiac surgical patient. 
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